Recent Advances in Marine-Derived Nanoformulation for the Management of Glioblastoma
Molecular Biotechnology · 2025-09 · 67 (9) · 3440-3453
DOI: 10.1007/s12033-024-01287-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Biotechnology, online erschienen am 26.09.2024. Verfasst von Chanam Melody Devi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, NETES Institute of Pharmaceutical Science, NEMCARE Group of Institutions, Mirza, Santipur, Kamrup, Assam, 781125, India. Hauptthemen laut MEDLINE: Glioblastoma, Antineoplastic Agents, Aquatic Organisms, Biological Products. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 83 Literaturangaben.
Abstract (Originalsprache)
Glioma is the most common and aggressive type of central nervous system tumor as categorized by the World Health Organization. Glioblastoma (GBA), in general, exhibits a grim prognosis and short life expectancy, rarely exceeding 14 months. The dismal prognosis is primarily attributed to the development of chemoresistance to temozolomide, the primary therapeutic agent for GBA treatment. Hence, it becomes imperative to develop novel drugs with antitumor efficacy rooted in distinct mechanisms compared to temozolomide. The vast marine environment contains a wealth of naturally occurring compounds from the sea (known as marine-derived natural products), which hold promise for future research in the quest for new anticancer drugs. Ongoing advancements in anticancer pharmaceuticals have led to an upswing in the isolation and validation of numerous pioneering breakthroughs and improvements in anticancer therapeutics. Nonetheless, the availability of FDA-approved marine-derived anticancer drugs remains limited, owing to various challenges and constraints. Among these challenges, drug delivery is a prominent hurdle. This review delves into an alternative approach for delivering marine-derived drugs using nanotechnological formulations and their mechanism of action for treating GBA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, NETES Institute of Pharmaceutical Science, NEMCARE Group of Institutions, Mirza, Santipur, Kamrup, Assam, 781125, India.
- Department of Pharmacognosy, NETES Institute of Pharmaceutical Science, NEMCARE Group of Institutions, Mirza, Santipur, Kamrup, Assam, 781125, India.
- Department of Pharmacology, NETES Institute of Pharmaceutical Science, NEMCARE Group of Institutions, Mirza, Santipur, Kamrup, Assam, 781125, India. piyongsola@yahoo.com.
Zitieren
APA
Devi, C. M., Deka, K., Das, A. K., Talukdar, A., & Sola, P. (2025). Recent Advances in Marine-Derived Nanoformulation for the Management of Glioblastoma. Molecular Biotechnology, 67(9), 3440-3453. https://doi.org/10.1007/s12033-024-01287-3
Vancouver
Devi CM, Deka K, Das AK, Talukdar A, Sola P. Recent Advances in Marine-Derived Nanoformulation for the Management of Glioblastoma. Molecular Biotechnology. 2025;67(9):3440-3453. doi:10.1007/s12033-024-01287-3
BibTeX
@article{Devi2025,
author = {Devi, Chanam Melody and Deka, Kangkan and Das, Amit Kumar and Talukdar, Apurba and Sola, Piyong},
title = {Recent Advances in Marine-Derived Nanoformulation for the Management of Glioblastoma},
journal = {Molecular Biotechnology},
year = {2025},
volume = {67},
number = {9},
pages = {3440--3453},
doi = {10.1007/s12033-024-01287-3}
}
EUVIMED